FIELD: pharmacology.
SUBSTANCE: composition according to this invention contains an active ingredient selected from a series of substituted quinazolinones and their pharmaceutically acceptable salts, stereoisomers, tautomers or hydrates, and additionally contains approximately 10 wt % to approximately 85 wt % of microcrystalline cellulose; approximately 4.0 wt % of sodium starch glycolate; approximately 0.5 wt % of magnesium stearate; and approximately 2.5 wt % of colloidal silicon dioxide; and prepared for peroral introduction and immediate release.
EFFECT: creation of new compounds that increase the bioavailability of substituted quinazolinones while maintaining stability, possibility of treatment and prevention of the abovementioned diseases.
15 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING QUINAZOLINONE DERIVATIVES | 2009 |
|
RU2520098C2 |
| PELLETISABLE (4'-TRIFLUOROMETHYLPHENYL)AMIDE (Z)-2-CYANO-3-HYDROXY-BUT-2-ENOIC ACID PREPARATION WITH IMPROVED STABILITY | 2010 |
|
RU2681079C2 |
| COMPOSITIONS OF PILL WITH IMMEDIATE RELEASE | 2010 |
|
RU2558798C2 |
| PREPARATION OF AND FORMULATION COMPRISING A MEK INHIBITOR | 2013 |
|
RU2669391C2 |
| PHARMACEUTICAL COMPOSITIONS COMPRISING AROMATASE INHIBITOR | 2012 |
|
RU2617510C2 |
| COMPOSITIONS OF STABLE TIACUMICINES | 2008 |
|
RU2484829C2 |
| PRO-MEDICATION COMPOSITION FOR STRUGGLE AGAINST HEPAPATITIS C VIRUS | 2006 |
|
RU2435592C2 |
| SUCCINIMIDE AND MALEIMIDE INHIBITORS OF CYTOKINS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHODS OF INHIBITION OF TUMOR NECROSIS α-FACTOR | 1996 |
|
RU2176242C2 |
| SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION AND METHOD FOR ITS PREPARING | 2002 |
|
RU2234915C2 |
| TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | 2004 |
|
RU2380093C2 |
